Article Sidebar
Published:
Jan 3, 2018Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Myricetin attenuates lung inflammation and provides protection against lipopolysaccharide-induced acute lung injury by inhibition of NF-κB pathway in rats
Abstract
Purpose: To investigate whether myricetin ameliorates lipopolysaccharide (LPS)-induced acute lung inflammation (ALI) in a rat model, and to elucidate the probable molecular mechanism of action involved.
Methods: Myricetin (10, 20 and 40 mg/kg) was administered to rats 30 min after intratracheally administering LPS (5 mg/kg). BALF protein concentration, lung wet-to-dry weight ratio, myeloperoxidase (MPO) activity, cytokine production and migration of inflammatory cells were evaluated.
Results: Myricetin significantly (p ≤ 0.05) attenuated lung inflammation as evident from the decreased wet-to-dry weight ratio of lungs, concentration of protein in the BALF, activity of MPO, cytokine production, and inflammatory cell migration. A decrease was also seen in TLR4, MyD88 and NF-κB expression. Additionally, an elevated antioxidant enzyme activity of superoxide dismutase (SOD), glutathione peroxidase (GPx) and catalase (CAT) was observed in all the treatment groups.
Conclusion: Myricetin provides protection against LPS-induced ALI. The underlying mechanisms of its anti-inflammatory action may include inhibition of NF-κB-mediated inflammatory responses.
Keywords: Acute lung injury, Anti-inflammatory, Myricetin, Inflammation, Cytokine, BALF, Flavonoid
